“We continue to execute and achieve key milestones across our pipeline of potential transformative medicines for patients with unmet needs,” said Saurabh Saha, Chief Executive Officer of Centessa. “We’re making good progress enrolling our registrational studies for SerpinPC in hemophilia B, with or without inhibitors, and are excited to share new data from the ongoing Phase 2a study of SerpinPC during a poster presentation at ASH in December. We also continue to advance our novel LockBody technology platform with LB101, a PD-L1xCD47 LockBody, which is in an ongoing Phase 1/2a clinical trial for the treatment of solid tumors.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CNTA:
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
- CNTA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
- Centessa announces dosing of first subject in registrational PRESent-3 study
- Centessa upgraded to Equal Weight from Underweight at Morgan Stanley
